New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for ...

People who took Zepbound had greater reductions in waist circumference and body weight, a study found.Fact checked by Nick ...

About 8 million American teens, or 23% of people ages 12 to 19, have obesity, up from 5% in 1980, according to U.S.

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Novo Nordisk ( NVO, Financials) is seeing more U.S. teens start treatment with its GLP-1 drug Wegovy; new data shows a 50% ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Cigna is reducing monthly out-of-pocket costs to $200 for patients using weight-loss drugs Wegovy and Zepbound. These ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. The randomized, controlled trial — called ...